Fig. 5From: Docking and dynamic simulation study of Crizotinib and Temozolomide drug with Glioblastoma and NSCLC target to identify better efficacy of the drugRMSD graph of ligand-free protein and ligand bounded protein complex of ALK proteinBack to article page